A Study of the Performance of Genome Sequencing as a Clinical Test to Identify Multifocal Lung Cancers for Treatment, versus Advanced Metastatic Disease

Overview

About this study

The purpose of this study is to assess the use and performance of a genome sequencing test to identify multifocal lung cancer tumors, which can be treated with surgery or radiation, and advanced stage metastatic lung cancer, which has the option of palliative or supportive care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Must be > 18 years of age
  • Presumed or known lung cancer
  • Undergoing bronchoscopy, CT guided lung biopsy, or lung resection as part of clinical care at Mayo Clinic Rochester
  • PFT's and other clinical determinates that show the subject is capable of tolerating a lung biopsy or resection
  • Non-pregnant and non-lactating
    • Women of child-bearing potential must have a negative urine or serum pregnancy test
  • Must be able to understand and willing to sign an IRB-approved informed consent document

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Marie Christine Aubry, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer